ストックスクリーナーアプリを入手
2.36
2.88%
-0.07
アフターアワーズ：
2.40
0.04
+1.69%
前日終値:
$2.43
開ける：
$2.45
24時間の取引高:
326.58K
Relative Volume:
0.48
時価総額：
$5.36M
収益：
-
当期純損益:
$-22.71M
株価収益率:
-0.2015
EPS:
-11.71
ネットキャッシュフロー:
$-18.24M
1週間 パフォーマンス:
-16.31%
1か月 パフォーマンス:
+31.84%
6か月 パフォーマンス:
-82.67%
1年 パフォーマンス:
-92.24%
1日の値動き範囲:
$2.2401
$2.47
1週間の範囲:
$2.2401
$3.04
52週間の値動き範囲:
$1.71
$55.00
Genprex Inc Stock (GNPX) Company Profile
GNPX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
2.36 | 5.52M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-01-26 | 開始されました | National Securities | Buy |
| 2019-04-29 | 開始されました | Noble Capital Markets | Outperform |
Genprex Inc (GNPX) 最新ニュース
Aug PreEarnings: Will Genprex Inc outperform tech stocksShort Setup & Safe Entry Point Identification - baoquankhu1.vn
Aug Patterns: Whats the outlook for TMD Energy Limiteds sectorWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
Genprex, Inc. Stock (GNPX) Opinions on GPX-002 Diabetes Therapy Data - Quiver Quantitative
Aug Spikes: How does Genprex Inc score in quality rankingsFed Meeting & High Accuracy Investment Signals - baoquankhu1.vn
Take Profit: Is Genprex Inc stock a defensive play in 20252025 Sector Review & Verified Stock Trade Ideas - Bộ Nội Vụ
Genprex Regains Nasdaq Compliance but Faces Ongoing Monitoring - The Globe and Mail
MSN Money - MSN
Genprex Regains Nasdaq Compliance - TradingView — Track All Markets
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Congressman who was top 2025 stock picker buys shares of $5M company you've never heard of - MSN
Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of - Benzinga
Rep. Tim Moore Purchases Shares of Genprex (NASDAQ:GNPX) - Defense World
Will Genprex Inc. stock remain a Wall Street favorite2025 Technical Patterns & Daily Oversold Stock Bounce Ideas - ulpravda.ru
Can Genprex Inc. stock beat market expectations this quarterShort Setup & Safe Entry Point Identification - ulpravda.ru
Can Genprex Inc. stock sustain market leadershipWeekly Trading Summary & AI Based Trade Execution Alerts - Улправда
PRN_FinancialWrapper | PR NewswireGenprex, Inc.Common Stock (Nasdaq:GNPX) Price Chart - FinancialContent
Why analysts upgrade Genprex Inc. stock2025 Market WrapUp & Risk Controlled Swing Alerts - ulpravda.ru
How Genprex Inc. stock reacts to inflationary pressuresJuly 2025 PreEarnings & Entry and Exit Point Strategies - Улправда
Is Genprex Inc. stock a bargain at current levelsSwing Trading Watchlist & Optimize Entry & Exit With Smart Signals - Улправда
Genprex Advances Diabetes Gene Therapy Program With Preclinical Milestones - Nasdaq
Genprex reports in vivo proof of concept for GPX-002 - BioWorld MedTech
Genprex reports positive data for diabetes gene therapy in animal studies - Investing.com Nigeria
Genprex advances GPX-002 diabetes gene therapy program - TipRanks
Genprex, Inc. Announces Updates on Diabetes Gene Therapy Program - TradingView — Track All Markets
Genprex Provides Clinical Update on Diabetes Gene Therapy Program - Barchart.com
Genprex Advances Diabetes Gene Therapy with Key Milestones Achieved in 2025 - Intellectia AI
What catalysts could drive Genprex Inc. stock higher2026 world cup usa national team semifinals young talents build up play odds analysis expert opinion - ulpravda.ru
Genprex reports positive preclinical results for GPX-002 diabetes therapy - MSN
Genprex Inc surges 9.44% amid market context - Intellectia AI
Genprex Reports Positive Preclinical Data for Diabetes Gene Therapy in Animal Studies; Shares Rise - marketscreener.com
Genprex Reports Positive Preclinical Data For Diabetes Gene Therapy Candidate GPX-002 - Nasdaq
Genprex Announces Positive Preliminary Preclinical Data from Stu - GuruFocus
Genprex reports positive data for diabetes gene therapy in animal studies By Investing.com - Investing.com South Africa
Genprex Reports Positive Preclinical Results for GPX-002 Diabetes Therapy - TipRanks
Genprex Announces Positive Preclinical Data for GPX-002 in Diabetes - TradingView — Track All Markets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies - PR Newswire
Genprex (GNPX) Stock Analysis Report | Financials & Insights - Benzinga Italia
Published on: 2025-12-29 06:37:03 - moha.gov.vn
Genprex reports potential compliance with Nasdaq equity listing rule By Investing.com - Investing.com Canada
Genprex (GNPX) awards 28,500 RSUs to Chief Medical Officer under 2018 plan - Stock Titan
Genprex (GNPX) CEO Ryan Confer reports 45,000 RSUs award - Stock Titan
Genprex (GNPX) grants director 9,000 RSUs after reverse stock split - Stock Titan
Genprex reports potential compliance with Nasdaq equity listing rule - Investing.com
Genprex Updates on Nasdaq Compliance Efforts - TradingView — Track All Markets
Street Watch: Will Genprex Inc stock split attract more investorsMarket Trend Review & Real-Time Stock Movement Alerts - moha.gov.vn
Aug Catalysts: How Genprex Inc. stock reacts to inflationary pressuresQuarterly Profit Review & Verified Chart Pattern Signals - moha.gov.vn
How Genprex Inc. stock performs in high volatility marketsInflation Watch & Free Real-Time Market Sentiment Alerts - Улправда
Momentum Shift: Why Genprex Inc stock remains on buy listsEarnings Risk Summary & Fast Moving Stock Watchlists - moha.gov.vn
Will Genprex Inc. (2DE0) stock benefit from mergers2025 Performance Recap & Long-Term Investment Growth Plans - Улправда
Genprex Inc (GNPX) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):